Regeneron Pharmaceuticals (REGN)
Health Care8 articles
Price chart
Why is REGN moving today?
-0.7%REGN is -0.7% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 13 hours ago
Regeneron Pharmaceuticals (REGN) overview
Regeneron is a biotechnology company known for Eylea and Dupixent.
REGN is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
Regeneron Pharmaceuticals trades on the NasdaqGS under the ticker symbol REGN. The most recent market data puts the share price at about $790.74. That is down 0.70% on the session. At that price the company is worth roughly $81.41B.
Over the past 52 weeks, REGN has traded between $572.75 and $859.34. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 19.6. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. REGN also pays a dividend. It yields around 0.48% at the current price.
Key statistics
Source: Yahoo Finance - quote as of 13 hours ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch REGN
REGN is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each REGN story as it breaks, and tags it bullish, bearish or neutral.
What moves REGN
- Earnings. REGN reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from REGN.
- Sector news. Health Care stocks often move together, so a rival's news can move REGN too.
Market Mood
Latest REGN news
Sanofi, Regeneron Plan $8 Billion Alliance Deal
Sanofi and Regeneron are planning to expand their alliance in a deal valued at up to $8 billion. The collaboration between the two companies aims to enhance their existing partnership in the pharmaceutical sector, potentially allowing them to increase their market presence and product offerings. This strategic expansion highlights the companies' commitment to growth and innovation in the industry. While the exact details of the deal are still unfolding, the significant financial investment underscores the importance of this partnership for both firms. For investors, this expanded alliance may signal increased revenue potential for Sanofi and Regeneron. The deal could lead to new product developments and strengthen their competitive position in the market. The $8 billion valuation of the deal is a substantial commitment and reflects the confidence both companies have in their joint strategic goals. This matters for ordinary investors as it indicates potential growth and increased market value for Sanofi (SAN) and Regeneron (REGN) through their strengthened alliance.
Read More: Sanofi, Regeneron Plan $8 Billion Alliance Deal
Regeneron Reports 73% Response Rate in Ovarian Cancer Drug Trial
Regeneron Pharmaceuticals reported a 73% response rate in its ongoing ovarian cancer drug trial. This high response rate demonstrates promising efficacy for the treatment under investigation. The results could lead to further development and eventual market release, which may impact Regeneron's revenue potential significantly. For investors, the success of this trial could be crucial, influencing future stock performance for Regeneron (REGN).
Read More: Regeneron Reports 73% Response Rate in Ovarian Cancer Drug Trial
Eli Lilly (LLY) selected for FDA's PreCheck pilot program
Eli Lilly (LLY) and Regeneron (REGN) are among the first seven companies selected for the FDA's PreCheck pilot program aimed at accelerating reviews of new pharmaceutical manufacturing facilities. The initiative allows regulators to review facilities during construction, potentially saving companies up to 14 months in review time. Lilly's facility in Lebanon, Indiana, and Regeneron's $2 billion site in Saratoga Springs, New York, are included in the program. This effort targets domestic drug production and involves companies producing biologic drugs and genetic medicines.
Read More: Eli Lilly (LLY) selected for FDA's PreCheck pilot program
Stocks Moving Premarket: Regeneron, Dominion Energy, Macy's
Premarket trading has seen significant movements for several stocks, including Regeneron, Dominion Energy, and Macy's. Key players in this market include Regeneron Pharmaceuticals, which has recently been the subject of speculation regarding their pipeline. The trading volume and price actions are indicative of investor sentiment ahead of the market open. Understanding these premarket shifts can provide insights into overall market trends and potential impacts on trading for the day.
Read More: Stocks Moving Premarket: Regeneron, Dominion Energy, Macy's
Regeneron (REGN) Stock Drops After Melanoma Drug Trial Failure
Regeneron Pharmaceuticals (REGN) recently reported that its key melanoma drug trial did not achieve the desired outcomes compared to Merck’s Keytruda. This failure is significant as it raises concerns about the effectiveness of Regeneron's treatments in a competitive oncology market. Following the announcement, Regeneron's stock price declined, impacting investor sentiment negatively. The precise percentage drop in stock value was not disclosed, but market reactions generally reflect uncertainty surrounding the company's future drug development prospects.
Read More: Regeneron (REGN) Stock Drops After Melanoma Drug Trial Failure
Regeneron (REGN) First-Quarter Earnings Show 19% Revenue Growth
Regeneron Pharmaceuticals (REGN) posted first-quarter revenue of $3.6 billion, a 19% increase year-over-year, surpassing analysts' expectations of $3.48 billion. Despite a 10% drop in Eylea sales to $941 million, Libtayo sales surged 54% to $438 million, and Dupixent sales reached $1.6 billion, up 36%. The company also initiated a new $3 billion share repurchase program following an $803 million buyback in Q1. Additionally, the FDA granted accelerated approval for Otarmeni, a gene therapy for hearing loss, further enhancing Regeneron's market potential.
Read More: Regeneron (REGN) First-Quarter Earnings Show 19% Revenue Growth
Regeneron (REGN) Offers Otarmeni Gene Therapy Free in U.S.
Regeneron Pharmaceuticals (REGN) announced its newly approved gene therapy, Otarmeni, will be offered for free in the U.S. while pricing in other countries is still undecided. CEO Leonard Schleifer indicated they are determining a fair price internationally. In clinical trials, 80% of participants saw hearing improvements, with estimates suggesting around 50 babies born annually in the U.S. with the condition. Analysts from Piper Sandler project peak sales of $130 million, emphasizing the limited financial impact due to the condition's rarity.
Read More: Regeneron (REGN) Offers Otarmeni Gene Therapy Free in U.S.
Regeneron (REGN) drug pricing deal lowers costs, offers free therapy
Regeneron (REGN) agreed to lower U.S. drug prices as part of a deal with President Trump, allowing for the first hearing-loss gene therapy to be offered for free to eligible U.S. patients following FDA approval. This agreement is part of a broader initiative involving 17 deals with pharmaceutical companies aimed at aligning U.S. drug prices with those in other developed nations. Regeneron's gene therapy, Otarmeni, has been projected to achieve peak sales of $130 million, offering significant potential market impact. The deal also includes a three-year exemption from tariffs on pharmaceutical products, which may influence pricing strategies.
Read More: Regeneron (REGN) drug pricing deal lowers costs, offers free therapyMore Health Care stocks
Frequently asked questions
Is Regeneron Pharmaceuticals in the S&P 500?
Yes. Regeneron Pharmaceuticals trades as REGN and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is REGN in?
REGN sits in the Health Care sector of the S&P 500.
Where can I find the latest REGN news?
Right here. This page collects recent REGN news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is Regeneron Pharmaceuticals's stock price?
REGN last traded at about $790.74. Prices move all through the session, so this is the latest quote rather than a live one.
What is Regeneron Pharmaceuticals's market cap?
REGN is worth roughly $81.41B. Market cap is the share price times the number of shares outstanding.
What is REGN's P/E ratio?
REGN trades at a trailing P/E ratio of about 19.6. The ratio compares the share price with earnings per share over the past year.